Similar articles for PMID: 15479865

Year	Number of Results
1968	1
1987	1
1990	1
1994	1
1996	1
2000	1
2002	1
2003	4
2004	3
2005	4
2006	5
2007	4
2008	12
2009	10
2010	2
2011	6
2014	1
2015	4
2016	1
2017	1
2018	2
2019	2
2024	0

1

Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.

Calabrese LH, Zein N, Vassilopoulos D. Calabrese LH, et al. Ann Rheum Dis. 2004 Nov;63 Suppl 2(Suppl 2):ii18-ii24. doi: 10.1136/ard.2004.028209. Ann Rheum Dis. 2004. PMID: 15479865 Free PMC article. Review.

2

Treatment of rheumatic diseases in patients with HCV and HIV infection.

Galeazzi M, Giannitti C, Manganelli S, Benucci M, Scarpato S, Bazzani C, Caporali R, Sebastiani GD. Galeazzi M, et al. Autoimmun Rev. 2008 Dec;8(2):100-3. doi: 10.1016/j.autrev.2008.07.009. Epub 2008 Aug 9. Autoimmun Rev. 2008. PMID: 18694850 Review.

3

Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.

Carroll MB, Bond MI. Carroll MB, et al. Semin Arthritis Rheum. 2008 Dec;38(3):208-17. doi: 10.1016/j.semarthrit.2007.10.011. Epub 2008 Jan 25. Semin Arthritis Rheum. 2008. PMID: 18221983 Review.

4

Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.

Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, Triolo G, Valentini G, Valesini G; GISEA Group. Ferri C, et al. J Rheumatol. 2008 Oct;35(10):1944-9. Epub 2008 Aug 1. J Rheumatol. 2008. PMID: 18688917

5

Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections.

Vassilopoulos D, Calabrese LH. Vassilopoulos D, et al. Curr Opin Rheumatol. 2007 Nov;19(6):619-25. doi: 10.1097/BOR.0b013e3282f05b63. Curr Opin Rheumatol. 2007. PMID: 17917544 Review.

6

The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature.

Domm S, Cinatl J, Mrowietz U. Domm S, et al. Br J Dermatol. 2008 Dec;159(6):1217-28. doi: 10.1111/j.1365-2133.2008.08851.x. Epub 2008 Sep 25. Br J Dermatol. 2008. PMID: 18945310 Review.

7

Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.

Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airò P. Zingarelli S, et al. J Rheumatol. 2009 Jun;36(6):1188-94. doi: 10.3899/jrheum.081246. Epub 2009 May 15. J Rheumatol. 2009. PMID: 19447932 Review.

8

Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ. Furst DE, et al. Ann Rheum Dis. 2004 Nov;63 Suppl 2(Suppl 2):ii2-ii12. doi: 10.1136/ard.2004.029272. Ann Rheum Dis. 2004. PMID: 15479866 Free PMC article. Review. No abstract available.

9

Mycobacterial disease in patients with rheumatic disease.

van Ingen J, Boeree MJ, Dekhuijzen PN, van Soolingen D. van Ingen J, et al. Nat Clin Pract Rheumatol. 2008 Dec;4(12):649-56. doi: 10.1038/ncprheum0949. Nat Clin Pract Rheumatol. 2008. PMID: 19037226 Review.

10

Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.

Winthrop KL. Winthrop KL. Nat Clin Pract Rheumatol. 2006 Nov;2(11):602-10. doi: 10.1038/ncprheum0336. Nat Clin Pract Rheumatol. 2006. PMID: 17075599 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

65 results

Results by year